CTKB vs IART
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
CTKB · Cytek Biosciences$6.12 ▼ 3.16%
IART · Integra Lifesciences$13.25 ▼ 2.21%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- CTKB +4.8%
- IART +6.2%
Head to head
| Metric | CTKB | IART |
|---|---|---|
| Price | $6.12 | $13.25 |
| Change today | ▼ 3.16% | ▼ 2.21% |
| Market cap | $800.40M | $1.03B |
| Return, 3 months | +37.8% | -20.6% |
| Return, year to date | +21.2% | +6.7% |
| Return, 1 year | +4.1% | +10.0% |
| P/E (TTM) | – | 77.9 |
| P/B | 2.5 | 1.0 |
| P/E percentile vs own 5y | 70th | 99th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +1.8% | +2.3% |
| Net profit growth (YoY) | -11.3% | +374.8% |
| Gross margin | 54.7% | 52.4% |
| Operating margin | -21.1% | 4.4% |
| Net margin | -39.1% | 0.8% |
| Return on equity | -23.2% | 0.7% |
| Analyst target vs. price | +18.5% | +13.2% |
| Analyst buy share | 100% | 14% |
| RSI (14) | 57 | 45 |
| 30-day volatility | 58.9% | 66.7% |
| Max drawdown, 1 year | -42.9% | -40.4% |
| Trend read | Strong uptrend | Strong downtrend |
| Analyst consensus | Buy | Hold |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- IART is the largest of the group by market value.
- IART has returned the most over the past year.
- IART is growing revenue fastest.
- IART keeps the most profit per dollar of sales.
- CTKB has been the calmest stock over the last 30 days.